CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net (loss) income	$ (421,205)	$ 74,704
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization, including patient equipment depreciation	290,419	248,835
Goodwill impairment	511,866	0
Equity-based compensation	17,284	16,784
Change in fair value of warrant liability	(31,886)	(17,145)
Reduction in the carrying amount of operating lease right-of-use assets	26,309	16,924
Reduction in the carrying amount of finance lease right-of-use assets	3,821	0
Deferred income tax (benefit) expense	(37,033)	18,058
Change in fair value of interest rate swaps, net of reclassification adjustment	(1,394)	(2,202)
Amortization of deferred financing costs	3,926	3,926
Other	350	(2,023)
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(10,043)	2,357
Inventory	12,769	(3,992)
Prepaid and other assets	10,956	4,211
Operating lease obligations	(26,959)	(16,794)
Operating liabilities	(23,780)	(66,696)
Net cash provided by operating activities	325,400	276,947
Cash flows from investing activities:
Purchases of equipment and other fixed assets	(248,816)	(248,511)
Payments for business acquisitions, net of cash acquired	(17,917)	(16,134)
Payments for cost method investments	(128)	(731)
Net cash used in investing activities	(266,861)	(265,376)
Cash flows from financing activities:
Proceeds from borrowings on long-term debt	50,000	0
Repayments on long-term debt	(75,000)	(15,000)
Repayments of finance lease liabilities	(4,558)	(14,219)
Payments for shares purchased under share repurchase program	(9,224)	(13,992)
Proceeds from the exercise of stock options	538	1,388
Proceeds received in connection with employee stock purchase plan	2,031	1,616
Payments relating to the Tax Receivable Agreement	(3,202)	0
Distributions to noncontrolling interest	(2,500)	(2,000)
Payments for tax withholdings from restricted stock vesting and stock option exercises	(5,253)	(2,690)
Payments of contingent consideration and deferred purchase price from acquisitions	(1,500)	(5,563)
Net cash used in financing activities	(48,668)	(50,460)
Net increase (decrease) in cash	9,871	(38,889)
Cash at beginning of period	46,272	149,627
Cash at end of period	56,143	110,738
Supplemental disclosures:
Cash paid for interest	113,083	97,389
Cash paid for income taxes	5,727	10,490
Noncash investing and financing activities:
Equipment acquired under finance lease obligations	0	1,335
Unpaid equipment and other fixed asset purchases at end of period	32,481	50,864
Assets subject to operating lease obligations	8,179	5,411
Operating lease obligations	(8,179)	(5,411)
Assets subject to finance lease obligations	19,726	0
Finance lease obligations	(19,726)	0
Deferred purchase price in connection with acquisitions	$ 50	$ 422